ABERA BIOSCIENCE AB (8WK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has a cash flow conversion efficiency ratio of -0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-815.00K ≈ $-952.82K USD) by net assets (€19.29 Million ≈ $22.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 8WK net asset quality index to measure how much of total assets are equity-financed.
ABERA BIOSCIENCE AB - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ABERA BIOSCIENCE AB earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
ABERA BIOSCIENCE AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energy Metals Ltd
AU:EME
|
-0.004x |
|
Wise Group AB
ST:WISE
|
0.075x |
|
Oxbridge Re Holdings Ltd
NASDAQ:OXBR
|
0.032x |
|
Pudjiadi Prestige Tbk
JK:PUDP
|
0.000x |
|
ILYA Co. Ltd
KQ:058450
|
-0.047x |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
-0.003x |
|
Dataprep Holdings Bhd
KLSE:8338
|
-0.366x |
|
PATERSON RESOURCES LTD
F:U40
|
N/A |
Annual Cash Flow Conversion Efficiency for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual cash flow conversion efficiency of ABERA BIOSCIENCE AB from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see ABERA BIOSCIENCE AB (8WK) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.29 Million ≈ $22.55 Million |
€-3.26 Million ≈ $-3.81 Million |
-0.169x | -638.52% |
| 2024-12-31 | €8.66 Million ≈ $10.12 Million |
€-198.00K ≈ $-231.48K |
-0.023x | +99.27% |
| 2023-12-31 | €5.66 Million ≈ $6.61 Million |
€-17.71 Million ≈ $-20.71 Million |
-3.132x | -166.86% |
| 2022-12-31 | €16.78 Million ≈ $19.62 Million |
€-19.69 Million ≈ $-23.02 Million |
-1.174x | -- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more